Is Sai Life Sciences the Best Stock in Its Sector? A Look at the Numbers

Sai Life Sciences CMP Rs 1,536 (16 Sep 2026). Market cap Rs 32,723 Cr. ROE 14.05%. P/E 90.47x versus Industry P/E 37.96x.

Updated: 16 Sept 2026 • 1:26 pm

Posted by:

Is Sai Life Sciences the Best Stock in Its Sector? A Look at the Numbers

Quick Answer

Sai Life Sciences is one of the names investors compare when screening the Healthcare sector, built on a 14.05% return on equity and a P/E of 90.47x against an Industry P/E of 37.96x. Sai Life Sciences Ltd provides contract research, development and manufacturing (CRDMO) services to global pharmaceutical and biotech companies across the drug development lifecycle. Whether Sai Life Sciences is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.

Is Sai Life Sciences the best stock in its sector? The stock trades on the NSE at Rs 1,536 as of 16 September 2026, within its 52-week range of Rs 783.85 to Rs 1,697.00. Sai Life Sciences Ltd provides contract research, development and manufacturing (CRDMO) services to global pharmaceutical and biotech companies across the drug development lifecycle.

Sai Life Sciences sits in the Healthcare sector, and its 14.05% ROE and 90.47x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector's Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

Table of Contents

About Sai Life Sciences

Sai Life Sciences Ltd provides contract research, development and manufacturing (CRDMO) services to global pharmaceutical and biotech companies across the drug development lifecycle. At a market capitalisation of Rs 32,723 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Sai Life Sciences the Best Stock in Its Sector?

Sai Life Sciences makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 14.05% ROE with a 90.47x P/E against the sector's 37.96x Industry P/E. Sai Life Sciences' 90.47x P/E is more than double the 37.96x Industry P/E and above Gland Pharma in this series, a rich premium built on its CRDMO growth positioning rather than current earnings alone.

Metric	Sai Life Sciences
CMP (NSE)	Rs 1,535.70
52-Week High / Low	Rs 1,697.00 / Rs 783.85
Market Cap	Rs 32,723 Cr
P/E (TTM) vs Industry P/E	90.47x vs 37.96x
P/B	13.17
ROE	14.05%
EPS (TTM)	Rs 17.03
Dividend Yield	0.00%
Debt to Equity	0.12

Compare Sai Life Sciences Against Other Healthcare Sector Stocks

How Sai Life Sciences Compares Against Its Healthcare Sector Peers

The table below sets Sai Life Sciences against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Sai Life Sciences	32,723	90.47	14.05%	0.12
Gland Pharma	48,215	42.71	9.92%	0.03
Emcure Pharmaceuticals	37,499	36.80	18.67%	0.31
Peer average (2 companies)	-	39.75	14.30%	0.17

Against this peer set, Sai Life Sciences's 14.05% ROE is below the 14.30% peer average, and its P/E of 90.47x runs above the peer average of 39.75x. Sai Life Sciences' 90.47x P/E is more than double the 37.96x Industry P/E and above Gland Pharma in this series, a rich premium built on its CRDMO growth positioning rather than current earnings alone.

What Makes Sai Life Sciences Worth Watching in Healthcare

Solid ROE for CDMO: A 14.05% ROE is a healthy figure for a contract research and manufacturing business serving global pharma clients.
Low leverage: A debt to equity ratio of 0.12 gives Sai Life Sciences flexibility to invest in R&D and manufacturing capacity.
Steep valuation premium: A 90.47x P/E against a 37.96x Industry P/E prices in continued strong growth in India's CRDMO and pharma outsourcing capacity.

Sai Life Sciences Valuation: Is It Justified?

Sai Life Sciences' 90.47x P/E is more than double the 37.96x Industry P/E and above Gland Pharma in this series, a rich premium built on its CRDMO growth positioning rather than current earnings alone. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Bata India the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Sai Life Sciences and other Healthcare sector stocks.

How to Track Sai Life Sciences Before You Invest

Before deciding whether Sai Life Sciences deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

Open the Univest Screener and search for Sai Life Sciences to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Sai Life Sciences earns a place in the best stock in its sector conversation on the strength of a 14.05% ROE and a P/E of 90.47x against a 37.96x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Is Sai Life Sciences the best stock in its sector?

Ans. Sai Life Sciences has a 14.05% ROE and trades at 90.47x P/E against a 37.96x Industry P/E, and compares below the peer average ROE of 14.30% in this article's named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Sai Life Sciences?

Ans. Sai Life Sciences was trading at Rs 1,535.70 on the NSE as of 16 September 2026, within its 52-week range of Rs 783.85 to Rs 1,697.00.

What sector does Sai Life Sciences belong to?

Ans. Sai Life Sciences is classified under the Healthcare sector on Univest.

How does Sai Life Sciences compare to its sector peers on P/E?

Ans. Sai Life Sciences's P/E of 90.47x is above the 39.75x average of the 2 named peers compared in this article.

What is Sai Life Sciences's return on equity?

Ans. Sai Life Sciences reported a return on equity of 14.05%, which is below the 14.30% average of its named peers in this comparison.

Should I invest in Sai Life Sciences based on its sector position?

Ans. Sai Life Sciences's sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.